ARTICLE | Company News
BioMosaics Inc., Toronto Hospital deal
December 8, 2003 8:00 AM UTC
BioMosaics acquired from the hospital exclusive worldwide rights to a diagnostic for hepatocellular carcinoma (HCC) that uses a monoclonal antibody to glypican 3 (GPC3). GPC3 is a glycophosphatidyl i...